FDA's next peptide compounding meeting: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF

By · Published · 6 min read · 7 sources, 6 checked at the source

Rows of empty seats facing a screen with an FDA logo in a large public meeting room on the FDA campus.
The Great Room, FDA Building 31, a meeting room used for public meetings. Illustrative photo. Photo: The U.S. Food and Drug Administration, Public domain. Image credits

In July, FDA's compounding advisers voted in favor of six peptides that FDA staff had recommended against, according to press reports. Three months later, HHS turned those six into a compounding enforcement policy. So people are now asking which peptides come next. FDA has already named them: five substances are on the agenda, starting with GHK-Cu and dihexa, for the next Pharmacy Compounding Advisory Committee meeting, set for sometime before the end of February 2027. Here is what is on the table, what FDA has said about each one, and why the July result matters.

Facts are as of October 30, 2026. Sources, with retrieval dates, are at the bottom.

The gist

  • FDA's meeting page says the committee will discuss GHK-Cu, dihexa acetate, cathelicidin (LL-37), PEG-MGF (pegylated mechano growth factor) and melanotan II for possible inclusion on the 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry bulks list. [V]
  • The meeting is due before the end of February 2027. When we checked on October 30, FDA had not set a time or place, and no Federal Register meeting notice had been published. [V]
  • Advisory committees give FDA non-binding recommendations. [V] In July, the committee backed all six peptides it reviewed, and HHS later wrote a compounding policy for those same six. [S]
  • FDA's own safety page lists concerns for all five substances, ranging from limited human data to published case reports. [V]
  • 5substances on the next committee agenda [V]
  • 6 of 6peptides the July 2026 committee voted for, per press reports [S]
  • 2 business dayshow far ahead of the meeting FDA plans to post materials [V]

Why this meeting matters more after July

The July 23-24 meeting is the reason this agenda is worth watching. Press reports said the committee voted in favor of all six peptides it reviewed, including BPC-157 by 8 to 6 and semax by 8 to 5, even though FDA staff had recommended against them. [S] On October 30, HHS published a notice in the Federal Register at 91 FR 68526. It says HHS won't bring enforcement cases over 503A compounding with those six. [V] HHS cited the July meeting as evidence of strong interest in compounding them. [V]

That sequence doesn't guarantee the next meeting will go the same way. It does show that a favorable vote can turn into a real change in access within a few months, even before any formal rulemaking. [S] Our October 29 report covers the HHS policy in full.

The five substances on the agenda

FDA's safety-risk page for compounding ingredients lists all five among nominations that were withdrawn from its interim category 2. [V] For each one, FDA states its concerns. We summarize them below in our own words, as FDA's views, not ours. The page is current as of April 22, 2026. [V] Note that MOTS-c appears on that same list, and HHS still included it in its six-peptide policy. [V]

  • Cathelicidin (LL-37). This is an antimicrobial peptide the human body makes. FDA says it lacks enough safety information to know whether the compounded form would cause harm. It also flags possible immune reactions and cites nonclinical findings on male reproduction and on tumor growth in some tissues. [V]
  • GHK-Cu. FDA's concern covers injectable routes only. For those, it flags possible immune reactions from aggregation and impurities and notes limited human data. [V] Topical GHK-Cu is a separate matter: FDA lists GHK-Cu in category 1, except for injectables. We covered the human studies here. [V]
  • Dihexa acetate. FDA says it found no human exposure data for any route. [V] Our dihexa explainer covers the animal research and the 2025 retraction.
  • Melanotan II. FDA flags possible immune reactions and cites published case reports of serious adverse events, including melanoma and a brain-swelling syndrome called PRES. [V]
  • PEG-MGF. FDA says it found no human exposure data for any route and lacks key safety information. [V]

“Advisory committees make non-binding recommendations to the FDA based on the expertise of their members.” [V]

FDA, PCAC meeting page

How the public can take part

FDA says it plans to publish a Federal Register notice and open a docket for comments on this meeting. [V] The notice will explain how to request a time slot to speak during the open public hearing. [V] The meeting will be available online, and FDA plans a live webcast with archived video afterward. [V]

When the notice publishes, we'll add the date, docket number and comment deadline to this page and to our policy timeline.

What a vote would and wouldn't do

  • A favorable vote is advice to FDA. Adding a substance to the 503A bulks list still takes rulemaking. [V] July showed that HHS can act on a vote through enforcement policy without waiting for that rulemaking. [V]
  • An unfavorable vote wouldn't change any law by itself either. [V]
  • No vote at all on one substance is possible too, if FDA changes the agenda before the meeting. [U]

Dates to watch

  1. Date not yet setFDA's Federal Register notice for the meeting, with docket and speaker sign-up [V]
  2. Date not yet setBriefing documents, due at least two business days before the meeting [V]
  3. About Nov. 13, 2026Comment window closes on HHS's six-peptide policy, counted two weeks from Oct. 30 [V]
  4. By end of Feb. 2027The committee meeting itself [V]

Limits and unknowns

  • The vote counts from July come from press reports, not an FDA transcript we reviewed. [S]
  • FDA's safety page lists these five as withdrawn category 2 nominations. It doesn't explain how that relates to the new agenda, and we didn't find an FDA statement that does. [U]
  • No date has been set, and FDA's page has been current as of April 15, 2026, since spring. [V]

We'll update this page when FDA posts the meeting notice.

Peptide Policy Watch

FDA's next peptide compounding meeting: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF

Published October 30, 2026 · https://peptidepolicywatch.com/2026/10/30/next-fda-compounding-advisory-meeting-ll-37-ghk-cu-dihexa/

Printable checklist

Questions for your clinician

General questions drawn from this page, to take to a clinician or pharmacist who knows your health history.

  1. Is this an FDA-approved medicine, a compounded drug, or something with no approval for human use?
  2. What do the studies in people show, how large and how long were they, and where can I read them?
  3. How might my own health history, conditions and current medicines change how this applies to me?
  4. Is there an official label or other primary document I can read, and who would know if something goes wrong?

Print view Select it, then use your browser’s Print command to print only this box.

Sources (retrieved October 30, 2026 unless noted)

  1. FDA, "Meeting of the Pharmacy Compounding Advisory Committee," content current as of April 15, 2026 [V] — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
  2. FDA, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," content current as of April 22, 2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  3. FDA, "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act," content current as of May 14, 2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  4. Federal Register, notice of availability for the HHS peptide policy, 91 FR 68526, FR Doc. 2026-22192, published October 30, 2026 [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  5. HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  6. AJMC, "FDA Panel Backs 6 Peptides for Compounding," July 31, 2026 (retrieved October 26, 2026) [S] — https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
  7. Federal Register, FDA agency page, checked for documents published since October 29, 2026 (no committee notice found) [V] — https://www.federalregister.gov/agencies/food-and-drug-administration

Spot a mistake? See how we source and our corrections policy.